Mammalian topoisomerase II enzymes are nuclear enzymes which play an important role in DNA replication, the formation of chromosome scaffolds, chromatin organisation, maintaining genomic stability, DNA recombination, and may be involved in DNA transcription and repair.'2 Two forms of eukaryotic topoisomerase II have been identified3: topoisomerase II-ot has a molecular weight of 170 kilodaltons and is encoded by chromosome 17; topoisomerase II-,B has a molecular weight of 180 kilodaltons and is encoded by chromosome 3.45 Topoisomerase II-ot and II-can be distinguished biochemically and pharmacologically, and their expression is regulated differentially.6 Topoisomerase II-ot is not detectable in GO cells, but its activity increases dramatically during S phase, peaks in G2-M, and then declines. By contrast, the P form remains constant throughout the cell cycle and is detectable in GO cells.7 Immunocytochemical studies have shown that topoisomerase II-,B is present almost exclusively in the nucleolus, whereas topoisomerase II-ot is localised to the nucleoplasm.8 Topoisomerase II-is thought to represent a structural element of the nucleolar remnant and to play a role in the regulation ribosomal gene transcription.9
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Methods
Tumour specimens from 63 patients with primary invasive ductal breast cancer attending Antwerp University Hospital were collected prospectively between January 1990 and June 1992. All biopsy specimens were immediately snap frozen and stored in liquid nitrogen until sectioned. Cryostat sections of the primary tumours were stained immunohistochemically. They were fixed for 10 minutes in a 3-7% neutral buffered formalin. After quenching endogenous peroxidase activity and a preincubation step with 10% normal swine serum (Dako, Glostrup, Denmark) in phosphate buffered saline (PBS), the cryostat sections were stained with a rabbit polyclonal antibody Topoisomerase II-ot nuclear immunoreactivity was quantified by counting at least 500 cells in different random fields, using a high power ( x 40) objective with a grid screen. Occasional cytoplasmic staining was not taken into account unless pronounced nuclear staining was also present. Results were expressed as per cent of cells staining positively for topoisomerase II-ot. For further statistical analysis, two groups of tumours were defined: those with 14% or less (low expression) and those with over 14% of nuclei staining positively (high expression). This distribution was chosen because numerically comparable patient groups were obtained.
Oestrogen and progesterone receptor content were determined using an enzyme immunoassay (Abbott, Chicago, Illinois, USA 
